The Impact of Obesity on the Pharmacology of Medications Used for Cardiovascular Risk Factor Control

Canadian Journal of Cardiology

Volumn 31, Issue 2, 2015, Pages 167-176

  Sankaralingam, Sowndramalingam ^a   Kim, Richard B ^b   Padwal, Raj S ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE PLUS BENAZEPRIL; ANTIDIABETIC AGENT; ATENOLOL; ATORVASTATIN; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DOXAZOSIN; FUROSEMIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; INSULIN ASPART; INSULIN LISPRO; METOPROLOL; NEBIVOLOL; PROPRANOLOL; ROSUVASTATIN; SOTALOL; VERAPAMIL; ANTIOBESITY AGENT;

BODY MASS; BODY SIZE; BODY SURFACE; BODY WEIGHT; CARDIOVASCULAR RISK; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; FAT MASS; HUMAN; LEAN BODY WEIGHT; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; CARDIOVASCULAR DISEASES; COMPLICATION; HEALTH; INCIDENCE; RISK FACTOR; TREATMENT OUTCOME;

ANTI-OBESITY AGENTS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; GLOBAL HEALTH; HUMANS; INCIDENCE; OBESITY; RISK FACTORS; TREATMENT OUTCOME;

EID: 84924933300     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.10.025     Document Type: Review

References (74)

1. World Health Organization. Media Centre. Obesity and overweight. Available at: . Accessed July 22,2014. http://www.who.int/mediacentre/factsheets/fs311/en/.
2. Ogden C.L., Carroll M.D., Kit B.K., Flegal K.M. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014, 311:806-814.
3. Padwal R.S. Obesity, diabetes, and the metabolic syndrome: the global scourge. Can J Cardiol 2014, 30:467-472.
4. Padwal R.S., Sharma A.M. Treating severe obesity: morbid weights and morbid waits. CMAJ 2009, 181:777-778.
5. Whitlock G., Lewington S., et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009, 373:1083-1096. Prospective Studies Collaboration.
6. Haslam D.W., James W.P. Obesity. Lancet 2005, 366:1197-1209.
7. Ashraf M.J., Baweja P. Obesity: the 'huge' problem in cardiovascular diseases. Mo Med 2013, 110:499-504.
8. Benet L.Z., Zia-Amirhosseini P. Basic principles of pharmacokinetics. Toxicol Pathol 1995, 23:115-123.
9. Fan J., de Lannoy I.A. Pharmacokinetics. Biochem Pharmacol 2014, 87:93-120.
10. Cornier M.A., Després J.P., Davis N., et al. Assessing adiposity: a scientific statement from the American Heart Association. Circulation 2011, 124:1996-2019.
11. Ellis K.J. Human body composition: invivo methods. Physiol Rev 2000, 80:649-680.
12. Sutcliffe J.F. Areview of invivo experimental methods to determine the composition of the human body. Phys Med Biol 1996, 41:791-833.
13. Roubenoff R., Kehayias J.J. The meaning and measurement of lean body mass. Nutr Rev 1991, 49:163-175.
14. Hanley M.J., Abernethy D.R., Greenblatt D.J. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010, 49:71-87.
15. Green B., Duffull S.B. Development of a dosing strategy for enoxaparin in obese patients. Br J Clin Pharmacol 2003, 56:96-103.
16. Kjellberg J., Reizenstein P. Body composition in obesity. Acta Med Scand 1970, 188:161-169.
17. Green B., Duffull S. Caution when lean body weight is used as a size descriptor for obese subjects. Clin Pharmacol Ther 2002, 72:743-744.
18. Green B., Duffull S.B. What is the best size descriptor to use for pharmacokinetic studies in the obese?. Br J Clin Pharmacol 2004, 58:119-133.
19. Duffull S.B., Dooley M.J., Green B., Poole S.G., Kirkpatrick C.M. Astandard weight descriptor for dose adjustment in the obese patient. Clin Pharmacokinet 2004, 43:1167-1178.
20. Forbes G.B., Welle S.L. Lean body mass in obesity. Int J Obes 1983, 7:99-107.
21. Womersley J., Durnin J.V., Boddy K., Mahaffy M. Influence of muscular development, obesity, and age on the fat-free mass of adults. JAppl Physiol 1976, 41:223-229.
22. Falagas M.E., Karageorgopoulos D.E. Adjustment of dosing of antimicrobial agents for body weight in adults. Lancet 2010, 375:248-251.
23. Cheymol G., Poirier J.M., Carrupt P.A., et al. Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers. Br J Clin Pharmacol 1997, 43:563-570.
24. Poirier J.M., Le Jeunne C., Cheymol G., et al. Comparison of propranolol and sotalol pharmacokinetics in obese subjects. JPharm Pharmacol 1990, 42:344-348.
25. Ghobadi C., Johnson T.N., Aarabi M., et al. Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance. Clin Pharmacokinet 2011, 50:809-822.
26. Blouin R.A., Warren G.W. Pharmacokinetic considerations in obesity. JPharm Sci 1999, 88:1-7.
27. Anastasio P., Spitali L., Frangiosa A., et al. Glomerular filtration rate in severely overweight normotensive humans. Am J Kidney Dis 2000, 35:1144-1148.
28. Nowack R., Raum E., Blum W., Ritz E. Renal hemodynamics in recent-onset type II diabetes. Am J Kidney Dis 1992, 20:342-347.
29. Diehl A.M. Nonalcoholic steatohepatitis. Semin Liver Dis 1999, 19:221-229.
30. Guzzaloni G., Grugni G., Minocci A., Moro D., Morabito F. Liver steatosis in juvenile obesity: correlations with lipid profile, hepatic biochemical parameters and glycemic and insulinemic responses to an oral glucose tolerance test. Int J Obes Relat Metab Disord 2000, 24:772-776.
31. Ratziu V., Giral P., Charlotte F., et al. Liver fibrosis in overweight patients. Gastroenterology 2000, 118:1117-1123.
32. Hunt C.M., Watkins P.B., Saenger P., et al. Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin Pharmacol Ther 1992, 51:18-23.
33. Hunt C.M., Westerkam W.R., Stave G.M., Wilson J.A. Hepatic cytochrome P-4503A (CYP3A) activity in the elderly. Mech Ageing Dev 1992, 64:189-199.
34. Chiney M.S., Schwarzenberg S.J., Johnson L.A. Altered xanthine oxidase and N-acetyltransferase activity in obese children. Br J Clin Pharmacol 2011, 72:109-115.
35. Lucas D., Farez C., Bardou L.G., et al. Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. Fundam Clin Pharmacol 1998, 12:553-558.
36. O'Shea D., Davis S.N., Kim R.B., Wilkinson G.R. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 1994, 56:359-367.
37. Langtry H.D., Balfour J.A. Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Drugs 1998, 55:563-584.
38. Shukla U.A., Chi E.M., Lehr K.H. Glimepiride pharmacokinetics in obese versus non-obese diabetic patients. Ann Pharmacother 2004, 38:30-35.
39. Bowman S.L., Hudson S.A., Simpson G., Munro J.F., Clements J.A. Acomparison of the pharmacokinetics of propranolol in obese and normal volunteers. Br J Clin Pharmacol 1986, 21:529-532.
40. Cheymol G., Poirier J.M., Barre J., Pradalier A., Dry J. Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers. JClin Pharmacol 1987, 27:874-879.
41. Cheymol G., Woestenborghs R., Snoeck E., et al. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur J Clin Pharmacol 1997, 51:493-498.
42. Wojcicki J., Jaroszynska M., Droździk M., et al. Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects. Biopharm Drug Dispos 2003, 24:211-218.
43. Galletti F., Fasano M.L., Ferrara L.A., et al. Obesity and beta-blockers: influence of body fat on their kinetics and cardiovascular effects. JClin Pharmacol 1989, 29:212-216.
44. MacMahon S.W., Macdonald G.J., Bernstein L., Andrews G., Blacket R.B. Comparison of weight reduction with metoprolol in treatment of hypertension in young overweight patients. Lancet 1985, 1:1233-1236.
45. Manrique C., Whaley-Connell A., Sowers J.R. Nebivolol in obese and non-obese hypertensive patients. JClin Hypertens (Greenwich) 2009, 11:309-315.
46. Le Jeunne C., Poirier J.M., Cheymol G., et al. Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers. Eur J Clin Pharmacol 1991, 41:171-174.
47. Stimpel M., Koch B., Weber M.A. Comparison between moexipril and atenolol in obese postmenopausal women with hypertension. Maturitas 1998, 30:69-77.
48. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2009, 39:215-231.
49. Abernethy D.R., Schwartz J.B. Verapamil pharmacodynamics and disposition in obese hypertensive patients. JCardiovasc Pharmacol 1988, 11:209-215.
50. Wofford M.R., Anderson D.C., Brown C.A., et al. Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 2001, 14:694-698.
51. Kato J., Yokota N., Tamaki N., et al. Differential blood pressure reductions by angiotensin receptor blocker plus calcium channel blocker or diuretic in elderly hypertension with or without obesity. JAm Soc Hypertens 2012, 6:393-398.
52. Weber M.A., Jamersen K., Bakri G.L., et al. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet 2013, 381:537-545.
53. Hsueh W.A., Shojaee A., Maa J.F., Neutel J.M. Efficacy of amlodipine/olmesartan medoxomil+/- HCTZ in obese patients uncontrolled on antihypertensive monotherapy. Curr Med Res Opin 2012, 28:1809-1818.
54. Roth E.M., Oparil S., Melino M., et al. Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis. JClinHypertens (Greenwich) 2013, 15:584-592.
55. Calhoun D.A., Jones D., Textor S., et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008, 51:1403-1419.
56. Kotchen T.A. Obesity-related hypertension: epidemiology, pathophysiology, and clinical management. Am J Hypertens 2010, 23:1170-1178.
57. Padwal R.S., Rabkin S., Khan N. Assessment and management of resistant hypertension. CMAJ 2014, 186:E689-E697.
58. Wang S., Majumdar S.R., Padwal R. BMI annual blood pressure measurements, and mortality in patients with obesity and hypertension: a retrospective cohort study. Blood Press Monit 2015, 20:32-38.
59. DeGorter M.K., Tirona R.G., Schwarz U.I., et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet 2013, 6:400-408.
60. Bordeaux B.C., Qayyum R., Yanek L.R., et al. Effect of obesity on platelet reactivity and response to low-dose aspirin. Prev Cardiol 2010, 13:56-62.
61. Gaglia M.A., Torguson R., Pakala R., et al. Relation of body mass index to on-treatment (clopidogrel+ aspirin) platelet reactivity. Am J Cardiol 2011, 108:766-771.
62. Tamminen M., Lassila R., Westerbacka J., Vehkavaara S., Yki-Jarvinen H. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obes Relat Metab Disord 2003, 27:907-911.
63. Westerbacka J., Yki-Järvinen H., Turpeinen A., et al. Inhibition of platelet-collagen interaction: an invivo action of insulin abolished by insulin resistance in obesity. Arterioscler Thromb Vasc Biol 2002, 22:167-172.
64. Trovati M., Anfossi G., Massucco P., et al. Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine-3', 5'-cyclic monophosphate and adenosine-3', 5'-cyclic monophosphate. Diabetes 1997, 46:742-749.
65. Trovati M., Mularoni E.M., Burzacca S., et al. Impaired insulin-induced platelet antiaggregating effect in obesity and in obese NIDDM patients. Diabetes 1995, 44:1318-1322.
66. Jaber L.A., Ducharme M.P., Halapy H. The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus. Ther Drug Monit 1996, 18:6-13.
67. Campbell P.J., Carlson M.G. Impact of obesity on insulin action in NIDDM. Diabetes 1993, 42:405-410.
68. Jaber L.A., Antal E.J., Slaughter R.L., Welshman I.R. The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics. Eur J Clin Pharmacol 1993, 45:459-463.
69. Gagnon-Auger M., du Souich P., Baillargeon J.P., et al. Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. Diabetes Care 2010, 33:2502-2507.
70. Parkner T., Dyrskog S.E., Laursen T., et al. Obesity does not influence the unique pharmacological properties of different biphasic insulin aspart preparations in patients with type 2 diabetes. Diabetes Obes Metab 2010, 12:414-420.
71. Gupta A., Braunwald E., McNulty S., et al. Obesity and the response to intensified diuretic treatment in decompensated heart failure: a DOSE trial substudy. JCard Fail 2012, 18:837-844.
72. Thummel K.E., Wilkinson G.R. Invitro and invivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998, 38:389-430.
73. Wilkinson G.R. Drug metabolism and variability among patients in drug response. NEngl J Med 2005, 352:2211-2221.
74. Tirona R.G., Lee W., Leake B.F., et al. The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 2003, 9:220-224.